Lonza Expands US Spray-Drying Capacity with Bend Facility

Lonza Group AG is further expanding its manufacturing footprint in the United States with the planned construction of a large-scale commercial spray-drying facility in Bend, Oregon. The project, part of the company’s broader strategy to enhance its contract development and manufacturing organization (CDMO) services, aims to establish Lonza as the leading provider of commercial-scale spray-drying PSD-4 capacity in the US. The facility is expected to be operational by 2029 and will create over 80 new jobs, reinforcing Lonza’s role as a key player in particle engineering and bioavailability enhancement for pharmaceuticals. The investment aligns with the company’s One Lonza strategy, leveraging its Lonza Engine to drive innovation and supply-chain resilience for critical therapies. Lonza will offer full spray-dried dispersion (SDD) capacity, supporting both clinical and commercial drug development, particularly for small molecules, biologics, and mRNA-based therapies. The facility’s PSD-4 units will allow for future scalability as demand grows, with additional upgrades including energy-efficient systems and enhanced emission controls. The expansion also positions Lonza closer to key pharmaceutical customers, supporting regionalized and resilient supply chains for life-saving treatments. The project underscores Lonza’s commitment to advancing pharmaceutical innovation while addressing the increasing complexity of drug formulations, driven by the need for improved bioavailability in modern drug pipelines.